Products

Zio XT ECG Monitoring System
iRhythm Technologies
Cardiology AI
The Zio XT ECG Monitoring System by iRhythm Technologies offers a wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis.
Zio AT ECG Monitoring System
iRhythm Technologies, Inc.
Cardiology AI
The Zio AT ECG Monitoring System by iRhythm Technologies is an FDA-cleared, wearable mobile cardiac telemetry (MCT) service offering continuous, AI-powered ECG monitoring for long-term arrhythmia detection and comprehensive reporting.
ZEUS System (Zio Watch)
iRhythm Technologies
Cardiology AI
iRhythm Technologies' ZEUS System (Zio Watch) is an FDA-cleared, AI-powered wearable for long-term continuous cardiac monitoring, specifically designed to detect and characterize Atrial Fibrillation (AFib) and other cardiac arrhythmias, providing actionable insights for physicians.

See all 5 products →

About iRhythm Technologies

iRhythm Technologies is a leading digital healthcare company at the forefront of cardiac monitoring solutions, leveraging advanced AI and machine learning. The company specializes in developing wearable biosensor devices, most notably the Zio® ECG monitor, which offers a discreet and patient-friendly approach to continuous, long-term cardiac monitoring for up to 14 days. This innovative service is designed to improve the detection and management of various cardiac arrhythmias.

For physicians, the iRhythm monitoring service provides a comprehensive end-to-end solution. It integrates an FDA-cleared AI with a deep-learned algorithm, clinically validated to be as accurate as expert cardiologists in detecting 13 classes of arrhythmias. The platform distills millions of heartbeats into clinically actionable information, generating physician-ready reports often reviewed by certified cardiographic technicians. This streamlined process aims to expedite diagnosis, facilitate informed referral decisions, and enhance the overall patient experience through comfortable wear and reduced retesting, ultimately transforming cardiac care by delivering better data, better insights, and better health.

Focus Areas

Ambulatory cardiac monitoring AI-driven ECG interpretation wearable biosensors cloud-based data analytics digital health solutions detection of cardiac arrhythmias prediction of cardiac arrhythmias prevention of cardiac arrhythmias atrial fibrillation sleep apnea diagnostics

Business Intelligence

Key InvestorsNovo, Norwest Venture Partners (NVP), New Leaf Venture Partners, Kaiser Permanente Ventures, St. Jude Medical, Mohr Davidow Ventures, Synergy Life Science Partners, Stanford University
PartnershipsEpic (EHR integration), Verily (Zio Watch, AFib solutions), Lucem Health (predictive AI for early arrhythmia detection), BioIntelliSense (multiparameter sensor technology)
TechnologyZio® ECG monitor (wearable biosensor), cloud-based data analytics, proprietary deep-learned AI algorithms, ZioSuite® portal, MyZio® app, EHR integration, developing a multivitals platform
FDA ClearancesAt least 4 distinct FDA 510(k) clearances/updates, including for Zio monitor design and AI capabilities (May 2021), the ZEUS System for Zio Watch (July 2022), and Zio AT device design updates (October 2024 and November 2024). cleared products (estimated)

What Physicians Need to Know

Ambulatory Cardiac Monitoring
iRhythm offers long-term continuous ambulatory cardiac monitoring for up to 14 days using discreet, patient-friendly wearable biosensors like the Zio XT and Zio AT patches, and the Zio Watch for AFib detection.
AI-driven ECG Interpretation
Their service includes an FDA-cleared deep-learned AI algorithm, clinically proven to be as accurate as cardiologists, capable of classifying 13 types of arrhythmia classes. This AI-powered analysis is further curated and verified by Qualified Cardiac Technicians (QCTs) to ensure high accuracy and actionable reports.
Wearable Biosensors
The Zio patch is a lightweight, water-resistant, and breathable adhesive device designed for patient comfort and high compliance. The Zio Watch, developed with Verily, provides an AI-powered smartwatch system for AFib detection and characterization.
Cloud-based Data Analytics
iRhythm utilizes a secure, cloud-enabled platform (AWS EC2) for data processing and analytics. This platform handles millions of heartbeats and patient reports, providing robust analysis and generating comprehensive end-of-wear reports for physicians.
Digital Health Solutions
The company offers an end-to-end monitoring service that includes device provision, patient logistics, centralized data analysis, and delivery of clinician reports. This is supported by the ZioSuite portal for clinicians and the MyZio patient app for symptom logging and education.
Detection of Cardiac Arrhythmias
iRhythm's solutions provide a significantly higher diagnostic yield for various cardiac arrhythmias, including Atrial Fibrillation (AFib), supraventricular tachycardia, ventricular tachycardia, and bradyarrhythmias, compared to traditional Holter and event monitors, especially for intermittent events.
Prediction & Prevention of Cardiac Arrhythmias
iRhythm is focused on leveraging earlier insights to predict and prevent cardiac disease. Through partnerships and predictive AI solutions, they aim to identify at-risk patients proactively for earlier cardiac monitoring and intervention.
Atrial Fibrillation (AFib)
A core specialization is AFib detection and characterization, with studies showing increased AFib diagnoses. The Zio Watch, in particular, is cleared for AFib detection and quantifying AFib burden over time, crucial for stroke prevention strategies.
Sleep Apnea Diagnostics (Cardiac Risk)
While primarily focused on cardiac monitoring, iRhythm's Zio XT has been explored in identifying cardiac risks, such as AFib, in asymptomatic patients with risk factors like sleep apnea, highlighting the interconnectedness of these conditions.
Physician Tip

For physicians, iRhythm Technologies offers a powerful toolset for accurate and timely cardiac arrhythmia diagnosis. The long-term continuous monitoring capabilities (up to 14 days) significantly increase the chances of detecting intermittent arrhythmias that might be missed by shorter-term methods, leading to a higher diagnostic yield and reduced need for retesting. The FDA-cleared deep-learned AI, combined with expert human review, provides highly accurate and actionable end-of-wear reports with 99% physician agreement, fostering diagnostic confidence. The patient-centric design of the Zio patch ensures high patient compliance, leading to more complete and reliable data. Furthermore, the end-to-end service, including seamless EHR integration and the ZioSuite portal, streamlines workflow, reduces administrative burden, and allows physicians to focus more on patient care and less on data management. This enables primary care physicians to efficiently assess patients for potential arrhythmias, expediting time to diagnosis and treatment plans, and supporting value-based care initiatives by improving outcomes and potentially reducing healthcare costs.

iRhythm's Zio service supports seamless integration into existing healthcare workflows through HL7-based EHR integration and Single Sign-On (SSO) via SAML. This helps reduce staff burden, automate processes, and accelerate patient care pathways.

Products by iRhythm Technologies

5 products in the directory

Zio XT ECG Monitoring System
iRhythm Technologies
Cardiology AI
The Zio XT ECG Monitoring System by iRhythm Technologies offers a wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis.
Zio AT ECG Monitoring System
iRhythm Technologies, Inc.
Cardiology AI
The Zio AT ECG Monitoring System by iRhythm Technologies is an FDA-cleared, wearable mobile cardiac telemetry (MCT) service offering continuous, AI-powered ECG monitoring for long-term arrhythmia detection and comprehensive reporting.
ZEUS System (Zio Watch)
iRhythm Technologies
Cardiology AI
iRhythm Technologies' ZEUS System (Zio Watch) is an FDA-cleared, AI-powered wearable for long-term continuous cardiac monitoring, specifically designed to detect and characterize Atrial Fibrillation (AFib) and other cardiac arrhythmias, providing actionable insights for physicians.
ZEUS System
iRhythm Technologies
Cardiology AI
The ZEUS System by iRhythm Technologies is an AI-powered software that analyzes ECG data from wearable biosensors for long-term continuous cardiac monitoring, aiding in the detection and characterization of arrhythmias like Atrial Fibrillation.
Zio ECG Utilization Software (ZEUS) System
iRhythm Technologies
Cardiology AI
The Zio ECG Utilization Software (ZEUS) System by iRhythm Technologies is an AI-powered, cloud-based platform that analyzes continuous ECG data from wearable Zio monitors to aid physicians in the diagnosis and management of cardiac arrhythmias.

What the Web Says

iRhythm Technologies is a digital healthcare company primarily known for its Zio cardiac monitoring solutions. Product reviews generally highlight the Zio patch's ease of use, comfort, and effectiveness in detecting arrhythmias over extended periods compared to traditional Holter monitors. However, some users report issues with adhesive causing skin irritation and the device detaching. Company and employer reviews are mixed, with some employees praising the culture, benefits, and opportunities for professional development, while others express concerns about management, work-life balance, compensation, and a perceived negative shift in company culture.

Overall: Mixed

Strengths

  • Zio patch is easy to use and comfortable for patients.
  • Extended wear time (up to 14 days) increases arrhythmia detection rates.
  • Water-resistant and unobtrusive design improves patient compliance.
  • Provides comprehensive reports for physicians, often preventing the need for repeat testing.
  • Some employees report good benefits, competitive pay, and opportunities for professional development.
  • Positive feedback on teamwork and supportive coworkers in some departments.

Limitations

  • Adhesive can cause skin irritation, rashes, and discomfort.
  • Device may detach prematurely due to adhesive issues.
  • Concerns about billing practices and difficulty contacting customer service for billing inquiries.
  • Mixed to negative reviews regarding management and leadership.
  • Some employees report poor work-life balance, mandatory overtime, and micromanagement.
  • Perceived negative shift in company culture over time.

Based on reviews from: Comparably, Indeed.com, Rannkly, Reddit, iRhythm (Official Website), Diagnostic and Interventional Cardiology, PMC (PubMed Central), YouTube, Better Business Bureau, GuruFocus

Last updated: 2026-07-19

Videos

News, demos, and interviews about iRhythm Technologies.

Loading videos...

Videos load interactively. If none appear, search YouTube for iRhythm Technologies →

View all on YouTube

Press & Coverage

GlobeNewswire
iRhythm Technologies Announces Japanese Regulatory Approval of the Ziou00ae ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence
iRhythm Technologies received regulatory approval from the Japanese Pharmaceutical and Medical Device Agency (PMDA) for its Ziou00ae fourteen-day, long-term continuous ECG monitoring system, making it the first product to offer arrhythmia monitoring with AI in Japan.
2024-09
GlobeNewswire
iRhythm Technologies Receives European Union's CE Marking Under Medical Device Regulation (EU MDR) for its Ziou00ae monitor and ZEUS System
iRhythm Technologies announced that its Zio monitor ECG System and ZEUS System received CE mark certification under the European Union's Medical Device Regulation 2017/745 (EU MDR), reinforcing its commitment to high-quality cardiac monitoring solutions globally.
2024-01
GlobeNewswire
iRhythm Technologies Announces Publication of Large-Scale Study in Heart Rhythm and New Data Presented at AHA Scientific Sessions 2025
iRhythm Technologies published a large-scale study in Heart Rhythm and presented new data at AHA Scientific Sessions 2025, highlighting that short-term monitoring can miss significant arrhythmias and that patient-reported symptoms are often not associated with arrhythmia events.
2025-11
MedTech Dive
iRhythm Discloses Data Stolen From Third-Party Applications in Cyberattack
iRhythm Technologies disclosed a cyberattack where data, including proprietary and protected health information, was stolen from third-party-hosted business applications.
2026-06
MD+DI
CMS Proposal Lifts iRhythm Reimbursement Rates, Analysts Bullish
CMS proposed a 3% increase in reimbursement rates for long-term cardiac monitoring in its CY2027 Physician Fee Schedule, which analysts believe signals stable growth for iRhythm Technologies.
2026-07
GlobeNewswire
iRhythm Holdings Announces First Quarter 2026 Financial Results
iRhythm Holdings reported first-quarter 2026 revenue of $199.4 million, a 25.7% increase from the same period in 2025, driven by increased volume of Zio services and operational efficiencies.
2026-04
Healthcare Dive
FDA hits iRhythm with warning letter over problems at heart monitor facility
The U.S. Food and Drug Administration issued a warning letter to iRhythm Technologies due to alleged nonconformities to medical device regulations at a facility manufacturing its heart monitors.
2023-06
GuruFocus
iRhythm (IRTC) Removed from Conviction List but Rating Remains Positive
William Blair removed iRhythm Technologies from its Conviction List after a six-month evaluation, though the firm maintained an 'Outperform' rating, indicating a cautious yet optimistic outlook for the company specializing in digital healthcare solutions for cardiac arrhythmias.
2026-07

Frequently Asked Questions

iRhythm's primary products are the Ziou00ae ECG monitors, which are wearable biosensors for ambulatory cardiac monitoring, including Zio XT, Zio monitor, and Zio AT. These devices utilize FDA-cleared, deep-learned AI algorithms for ECG interpretation, which are proven to be as accurate as expert cardiologists in diagnosing arrhythmias like atrial fibrillation. The AI processes recorded data, which is then curated and verified by Qualified Cardiac Technicians to ensure accuracy.
iRhythm's Zio service provides continuous, long-term ECG monitoring for up to 14 days, with a 21-day MCT solution planned, enabling comprehensive detection of various cardiac arrhythmias, including atrial fibrillation. This extended monitoring period, coupled with high patient compliance (98-99%), results in a higher diagnostic yield and reduced retest rates compared to traditional Holter monitoring. This facilitates earlier and more accurate diagnosis, which is crucial for managing conditions like silent AFib and preventing serious cardiac events.
Patients wear a Zio biosensor that continuously collects ECG data, which is then uploaded to iRhythm's cloud-based platform. The data undergoes analysis by an FDA-cleared AI algorithm and is further curated by Qualified Cardiac Technicians to generate comprehensive, clinically actionable end-of-wear reports. These reports and patient management tools are accessible through the ZioSuiteu00ae portal and can be seamlessly integrated into Electronic Health Record (EHR) systems, including Epic Aura, to streamline physician workflows and enhance data accessibility.
iRhythm's Zio monitor system is typically billed under Category 1 CPT codes, such as 93243 for 48 hours to 7 days of monitoring and 93247 for 7 to 15 days. While iRhythm strives for broad insurance coverage and manages the technical component of claims, individual patient coverage can vary, and they offer patient financial navigators and assistance programs for out-of-network situations or financial hardship. Reimbursement rates have experienced fluctuations but have shown recent positive adjustments.
iRhythm Technologies provides extensive support and education for healthcare professionals through platforms like iRhythm Academy. This includes on-demand learning modules, expert-guided tutorials on Zio products and services, and clinically relevant content on arrhythmia detection and best practices in ambulatory cardiac monitoring. Additionally, provider support is available 24/7 via phone to assist with any monitoring needs.
Yes, iRhythm is actively expanding into sleep disorder diagnostics, recognizing the significant overlap between sleep apnea and atrial fibrillation, with pilot projects already underway. The company plans to integrate new photoplethysmography (PPG) sensors into its devices to measure SpO2, heart rate variability, and respiratory rate, creating a multivitals platform for diagnosing new classes of diseases beyond cardiac arrhythmias. Furthermore, iRhythm is focused on developing predictive AI solutions for earlier identification of arrhythmias in at-risk patient populations.
iRhythm holds a leading market position in digital healthcare, demonstrating consistent revenue growth and a positive outlook for profitability and free cash flow. The company has established strategic partnerships, including collaborations with Verily for AFib management solutions and Lucem Health for predictive AI in early arrhythmia detection. iRhythm has also achieved significant EHR integration with major platforms like Epic Aura, indicating strong market penetration and operational stability.

Investors

Who's funded iRhythm Technologies.

Related Companies

Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]

TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]

Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]

Avie is operated by AVIE TECNOLOGIA LTDA, headquartered in Santo André, São Paulo, Brazil. Avie provides WhatsApp reception in Brazilian Portuguese, appointment scheduling, rescheduling and cancellations through Google Calendar or Feegow, clinic CRM, follow-up messages and an online booking website. Clinic staff can review conversations and take over when human support is needed. Clinic CRM […]

Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]

Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.